Your Comprehensive Guide to Dry AMD & GA Preclinical Therapeutics Development
The 5th Dry AMD & GA Therapeutics Summit returns to tackle key challenges facing discovery and translational scientists. Built with the industry’s specific needs in mind, this year’s agenda spans discovery to early clinical content. This is your one stop shop to advance and accelerate the development of safe, effective and accessible dry AMD & GA therapeutics by uncovering cutting-edge advances.
Robust new content for 2024 includes overcoming the major preclinical challenges including new preclinical models recapitulating retinal microenvironment, validating new drug targets beyond complement and inflammasome systems, identifying novel imaging biomarkers, and regulatory enabled clinical endpoints for faster approvals!
Top 5 Unmissable Highlights:
Accelerate ophthalmic drug delivery from oral and topical cell and gene therapy, for longer lasting, less invasive deliveries with Sanofi, Novartis and GelMEDIX
Leverage AI models to develop imaging biomarkers and endpoints for earlier detection of macular degeneration with Apellis
Examine utilizing genomics, proteomics and histological studies to identify therapeutic targets and back translate clinical data with AbbVie, Sanofi and Aviceda
Optimize phase 1 clinical trial execution with novel regulatory approved endpoints, retinal imaging and appropriate patient selection with Genetech
Delve into innovations in gene and cell therapy from spatiallytargeted laser gene delivery to cell replacement therapy with Nanoscope Therapeutics and GelMEDIX
Who Will You Meet?
Connect with senior biopharma leaders from Apellis, Boehringer Ingelheim, AbbVie, Genentech, Sanofi, Novartis, Aviceda, ONL Therapeutics
What Your Peers Have to Say:
‘’Focused discussion, building up new networks, and sharing cutting-edge sciences’’
Scientist, National Eye Institute
‘‘Almost complete coverage of assets under development and great forthrightness of the presenting speakers’’
Chief Executive Officer, Drusolv
‘’Generally excellent presentations but the most important are the Q&A discussions. People were open to learn and teach each other.’’
Chief Scientific Advisor, Tacit Therapeutics